Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcadia Biosciences (RKDA) Research & Development (2016 - 2025)

Arcadia Biosciences' Research & Development history spans 12 years, with the latest figure at $9000.0 for Q2 2025.

  • For Q2 2025, Research & Development fell 10.0% year-over-year to $9000.0; the TTM value through Dec 2025 reached $9000.0, down 83.02%, while the annual FY2025 figure was $9000.0, 83.02% down from the prior year.
  • Research & Development reached $9000.0 in Q2 2025 per RKDA's latest filing, down from $13000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.2 million in Q1 2021 to a low of $6000.0 in Q1 2024.
  • Average Research & Development over 5 years is $345294.1, with a median of $255000.0 recorded in 2022.
  • The largest YoY upside for Research & Development was 60.0% in 2024 against a maximum downside of 98.33% in 2024.
  • A 5-year view of Research & Development shows it stood at $561000.0 in 2021, then decreased by 10.87% to $500000.0 in 2022, then crashed by 98.2% to $9000.0 in 2023, then skyrocketed by 44.44% to $13000.0 in 2024, then crashed by 30.77% to $9000.0 in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Research & Development are $9000.0 (Q2 2025), $13000.0 (Q4 2024), and $24000.0 (Q3 2024).